Abstract |
Pathways adopted by developing cancer cells for evasion of cellular surveillance mechanism deserve attention for therapeutic exploitation as well as for better prognosis. A novel mitotic kinase, PDZ-binding kinase or PBK, which is upregulated in a variety of neoplasms including hematological malignancies, has been the focus of our attention with a goal to understand its role in malignant conversion and to examine as a possible new therapeutic target in disparate types of cancer. Earlier, we reported that PBK expression was downregulated during macrophage differentiation of HL60 promyelocytic leukemia cells, during doxorubicin-induced growth arrest in G2/M phase and that PBK was regulated by cell cycle-specific transcription factors E2F and CREB/ATF. Here, we demonstrate that HT1080 fibrosarcoma cells become adapted to doxorubicin-induced DNA damage checkpoint upon ectopic expression of a phosphomimetic mutant of PBK as indicated by the accumulation of polyploid cells. Aberrant entry into the mitotic phase by these cells is suggested by the appearance of a mitotic phase-specific marker, MPM-2. We propose that the effect is due to downregulation of p53 caused by direct physical interaction with PBK as detected by both a biochemical means as well as by yeast two-hybrid analysis. Together, our studies provide a plausible explanation for the role of PBK augmenting tumor cell growth following transient appearance in different types of progenitor cells in vivo as reported.
|
Authors | Asit K Nandi, Tamara Ford, Daniel Fleksher, Brian Neuman, Aaron P Rapoport |
Journal | Biochemical and biophysical research communications
(Biochem Biophys Res Commun)
Vol. 358
Issue 1
Pg. 181-8
(Jun 22 2007)
ISSN: 0006-291X [Print] United States |
PMID | 17482142
(Publication Type: Journal Article)
|
Chemical References |
- Antibiotics, Antineoplastic
- Cell Cycle Proteins
- Tumor Suppressor Protein p53
- Doxorubicin
- Protein Serine-Threonine Kinases
- Mitogen-Activated Protein Kinase Kinases
- PDZ-binding kinase
|
Topics |
- Antibiotics, Antineoplastic
(pharmacology)
- Cell Cycle
- Cell Cycle Proteins
(metabolism)
- Cell Line, Tumor
- DNA Damage
- Down-Regulation
- Doxorubicin
(pharmacology)
- Humans
- Mitogen-Activated Protein Kinase Kinases
- Mutation
- Protein Binding
- Protein Serine-Threonine Kinases
(biosynthesis, genetics, physiology)
- Tumor Suppressor Protein p53
(metabolism)
|